Rilzabrutinib FDA Approved for Idiopathic Thrombocytopenia Purpura

rilzabrutinib (Wayrilz) Approved for Immune Thrombocytopenia (ITP) – A Summary

Here’s a summary of the key details from the provided text regarding the FDA approval of rilzabrutinib (Wayrilz) for Immune Thrombocytopenia (ITP):

Key Takeaways:

FDA Approval: The FDA has approved rilzabrutinib (Wayrilz) from Sanofi as a treatment for ITP, aiming to improve patient outcomes and quality of life.
Mechanism of Action: rilzabrutinib has a “differentiated mechanism of action” suggesting it works differently than existing treatments.
LUNA 3 Study: The approval is based on the Phase 3 LUNA 3 clinical trial (NCT04562766).
Study Design: The study involved adults and adolescents with persistent or chronic ITP, comparing rilzabrutinib (400mg twice daily) to placebo over a period including double-blind, open-label, and follow-up phases.
Primary Endpoint: The primary goal of the study was to achieve a durable platelet response – maintaining platelet counts of ≥50,000/μL for at least 8 of the last 12 weeks without needing rescue therapy.
Key Results (Adult Patients):
Platelet Response: 65% of patients on rilzabrutinib achieved a platelet response (≥50,000/μL or ≥30,000-<50,000/μL and doubled from baseline) compared to 33% on placebo. Durable Platelet response: 23% of rilzabrutinib patients achieved a durable response at week 25,compared to 0% on placebo (P < .0001). 29% achieved a durable response. Bleeding: Rilzabrutinib substantially improved bleeding symptoms (P = .0006).
rescue Therapy: The need for rescue therapy was reduced by 52% with rilzabrutinib (P = .0007).
Fatigue: Clinically meaningful improvements in fatigue were observed as early as week 13 (P = .01), and were sustained.
Quality of Life: Improvements were also seen in other quality-of-life domains.
* Adolescent Data: Results from the adolescent portion of the study are still ongoing.

In essence, rilzabrutinib demonstrates notable efficacy in increasing platelet counts, reducing bleeding, decreasing the need for rescue therapy, and improving fatigue and overall quality of life for adults with ITP.